



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

(19)

(11) Publication number:

0 043 254  
A1

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: 81302895.8

(51) Int. Cl.<sup>3</sup>: A 61 K 9/26

(22) Date of filing: 26.06.81

(30) Priority: 28.06.80 DE 3024416

(43) Date of publication of application:  
06.01.82 Bulletin 82/1

(84) Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE

(71) Applicant: GÖDECKE AKTIENGESELLSCHAFT  
Salzufer 16  
D-1000 Berlin 10(DE)

(72) Inventor: Augart, Helmut  
Tannenweg 28a  
D-7808 Waldkirch(DE)

(74) Representative: Jones, Michael Raymond et al,  
Haseltine Lake & Co. 28 Southampton Buildings  
Chancery Lane  
London WC2A 1AT(GB)

(54) Retarded release pharmaceutical composition and process for producing the same.

(57) A pharmaceutical composition with a retarded liberation of an active material and a process for producing the same are disclosed. An active material in finely divided form is mixed with both a finely divided high melting lipid or lipid component and a finely divided low melting lipid or lipid component, the resulting mixture is brought to a temperature which is above the melting point of the low melting component but below the melting point of the high melting component and the mixture, after melting of the low melting component, is allowed to cool to below the melting point thereof and subsequently worked up to give a finished pharmaceutical composition which has a controlled retarded liberation and which is safe, easy and not expensive to produce.

EP 0 043 254 A1

-1-

RETARDED RELEASE PHARMACEUTICAL COMPOSITION AND  
PROCESS FOR PRODUCING THE SAME

This invention relates to retarded release pharmaceutical compositions, i.e. pharmaceutical compositions with a retarded liberation of active material, such compositions being known as retard compositions; and to a process for producing such compositions.

A number of processes are known for the production of pharmaceutical compositions in retard form. Many of the known processes suffer from the substantial disadvantage that organic solvents are needed for their production, whereas others require the use of expensive or physiologically undesirable adjuvants.

In order to avoid these disadvantages, attempts have been made to use lipid materials for the production of retard compositions by embedding particles of active materials in lipid materials. A large number of such lipid materials are available and many processes have been described for the production of retard forms using lipid materials. Normally, certain swelling agents or disintegrating agents are added to the formulations in order to prevent compressed forms made from active materials embedded in such lipid materials liberating the active materials too slowly or in order to prevent the danger that some of the thus formulated active material is not liberated at all during passage through the body and can thus be resorbed. Thus, these lipid materials perform

a control function.

In the case of the production of retard forms in which the embedding of the active material in the lipid material represents the actual retard principle, 5 the lipid materials normally employed have a melting point which, as a rule, is in the range from 80 to 90°C. In this case, it is preferable to melt the lipid material or mixture of lipid materials and slowly to introduce the active materials or possibly 10 mixtures thereof with adjuvant materials into the melt, taking care that there is no localised cooling since otherwise disturbing inhomogeneities will arise.

It is advantageous to use lipid materials which are available in powdered form, because previously 15 prepared homogeneous mixtures of active materials and lipid materials can be heated above the melting temperature of the lipid materials, whereby embedding takes place. These masses can be converted into a granulate form by granulation during the cooling or 20 by grinding after the cooling. This process is admittedly economical insofar as it avoids the use of organic solvents; however, it does involve very considerable disadvantages, namely the use of steam-heated kettles and hot melts involves the danger 25 of accidents, and only very temperature-stable active materials can be worked up at the relatively high melting temperatures involved.

In order to avoid high melting temperatures, retard tablets have also been produced on the basis of lipids 30 by mixing lipid materials with melting points preferably in the range from 55 to 88°C, with active materials at ambient temperature and then pressing the mixture obtained into tablets [see Federal Republic of Germany Patent Specification No. 1,492,123]. However, this 35 process also is unsatisfactory because the pharmaceutical compositions thus produced always have a certain porosity which cannot be eliminated by increasing the amount of pressure applied. Such porosity results in

undesirable inhomogeneities and a rapid disintegration which can scarcely be controlled.

A further solution to the problem was sought by mixing particles of pharmaceutical materials with a wax additive material which is solid at ambient temperature but melts at a temperature at which the pharmaceutical material is not disadvantageously affected, followed by pressing the resulting mixture to form tablet cores and providing the tablet cores with a coating which keeps its shape at a temperature at which the wax additive material melts (see Federal Republic of Germany Patent Specification No. 1,617,657). The coated cores thus produced were then heated to above the melting point of the wax additive material, and, after cooling, were ready for use. This very laborious depot process had, in turn, the disadvantage that it is only possible to use active materials which are stable at the high temperatures used for melting the wax additive material in the coated cores.

Surprisingly, we have now found that for embedding an active material by melting a lipid or lipoid component, it is not necessary entirely to heat this component to a high temperature but that complete embedding can be achieved at considerably lower temperatures when the active material to be retarded is mixed with mixture of a high melting lipid or lipoid component and a low melting lipid or lipoid component, and the resulting mixture of active material and lipid or lipoid components is heated only to above the melting temperature of the low melting component .

Thus, according to one aspect of the present invention, there is provided a process for the production of a pharmaceutical composition with a retarded liberation of an active material, wherein an active material in finely divided form is mixed with both a finely divided high melting lipid or lipoid component and a finely divided low melting lipid or lipoid component, the resulting mixture of active material

and lipid or lipoid components is brought to a temperature which is above the melting point of the low melting component but below the melting point of a high melting component, and the resulting mixture, after melting of the low melting component, is allowed to cool to below melting point thereof and subsequently worked up to give a finished pharmaceutical composition.

According to another aspect of the present invention, there is provided a pharmaceutical composition with a retarded liberation of active material, the pharmaceutical composition comprising the active material in finely divided form, a finely divided high melting lipid or lipoid component, and, acting as a means for holding together the active material and the high melting lipid or lipoid components, a low melting lipid or lipoid component which has been caused to melt and subsequently to re-solidify.

The terms "low melting" and "high melting" as used herein in relation to the lipid or lipoid components indicate in relative terms the melting points of those components.

The lipid or lipoid components used can be conventional water-insoluble support materials, for example fatty alcohols and especially higher alkanols containing more than 13 and especially 16 to 20 carbon atoms, such as cetyl and stearyl alcohol, as well as mixtures thereof. Use can also be made of fatty acids which bring about a liberation of the active material dependent upon the pH, especially higher alkane-carboxylic acids, for example stearic acid. Glycerides, especially hydrogenated vegetable oils, such as hydrogenated cottonseed oil or castor oil, as well as mono-, di- and triesters of glycerol with palmitic acid or stearic acid or mixtures thereof can also be used. Furthermore, pulverised, wax-like materials of vegetable, animal, mineral or synthetic origin can be used. The lipophilic salts of fatty

-5-

acids, such as magnesium stearate, are also very suitable. It is only necessary that the retarding material is stable in the intended temperature range, is physiologically inert, and does not react with the pharmaceutically active material.

The high melting component preferably has a melting point above 70°C, there being no upper limit because this component, according to the present invention, does not have to be melted. However, a temperature range of from 80 to 100°C is preferred.

The low melting component must have a melting point below that of the high melting component; when the high melting component has a melting point above 70°C, the low melting component preferably melts below 70°C. The lower limit is determined by the lowest temperature at which the mixture can be worked up. Thus, below 30°C., the mixture begins to become increasingly smeary so that, for normal use, the lower limit of the melting point of the low melting component should be about 30°C, and, in practice, the preferred range is from 50. to 60°C.

The weight ratio of the two lipid or lipoid components can be varied within very wide limits. In practice, weight ratios of from 1:9 to 9:1 are completely acceptable. However, in most cases, use is made of mixtures of lipid or lipoid components with a weight ratio of from 1:5 to 5:1 and preferably of 1:3 to 3:1. The determination of the most favourable weight ratio can be carried out empirically, without difficulty, for every mixture.

Important parameters are the particle size and the amount of the active and additional materials. Thus, on melting, the liquid, low melting lipid or lipoid component can be regarded as filling the hollow spaces which are formed by the adjacent particles of the high melting lipid or lipoid component and of the adjuvant and active materials, a product being obtained in which, with the lower melting component

-6-

resolidified, the particles of the higher melting component and those of the adjuvant and active materials can be regarded as being embedded like gravel in concrete in which the solidified melt of the lower melting component is like the cement.

The composition of the present invention, which is the product of the process of the present invention, has, surprisingly, a pharmaceutical quality which does not differ from that of the previously known products manufactured by melting at much higher temperatures. The pharmaceutical formulations of the present invention are characterised by a uniform liberation of the active material over a long period of time. In particular, the liberation can be outstandingly well controlled by means of embedding in the mentioned lipid or lipoid components.

However, the process according to the present invention has the following considerable advantages in comparison with the prior art:

- 20 1) the active materials can be worked up much more gently at the low temperature;
- 2) owing to the low working temperature used, the danger of serious accidents is practically completely excluded;
- 25 3) the partial melting at a low temperature results in a considerable saving of energy; and
- 4) the apparatus used can be of substantially simpler construction (instead of steam-heated, double-walled mixers, it is possible to employ simple vessels operated with the use of hot water) and, if friction mixers and extruders are used, additional heating can be completely omitted.

The process of the present invention can be carried out in the following manner: a powdered mixture is first prepared of the active material or materials, of the lipid or lipoid components as well as of any conventional filling materials and disintegrating materials or swelling agents as liberation controlling components.

After homogeneous mixing, the mixture obtained is heated, while stirring, until the low melting component melts and the mass starts to sinter.

5 After complete melting of the low melting component air is forced out, possibly with the application of mechanical pressure, so that, after cooling, a practically pore-free sintered mass is obtained.

10 Examples of suitable filling materials which can be used include lactose, saccharose and calcium phosphate. Disintegrating agents or swelling agents which serve to control the liberation of the active materials are, for example, water-soluble or water-swellable materials, such as methyl cellulose, various synthetic polymers, natural materials, for example guar gum, and, 15 preferably, carboxymethylcelluloses.

The apparatus used can be, for example, a low speed mixing kneader or a high speed rapid mixer with mixing propellers.

20 The above described melt granulates can also be produced in fluidised bed granulators or in fluidised bed driers as the necessary temperatures can easily be achieved in such apparatus. Friction mixers are also suitable as, in that case, if desired, heating does not have to be carried out because the powder 25 mixtures heat up sufficiently in a few minutes at 1000 to 1500 r.p.m. Finally, cogwheel granulating machines can also be used as they permit a continuous operation with a very high throughput capacity. The powder mixtures can even be extruded non-porous at temperatures 30 of about 50°C with a little pressure.

After melting and before cooling, the mass is preferably additionally positively compressed by means of appropriate devices, for example extruders or friction mixers.

35 After this compressing, the mass can be granulated in any appropriate manner during cooling or can be granulated after cooling is complete. If desired, lubricants can be added to the granulate. The granulate can be pressed to give tablets, the active material.

liberation of which can be adjusted by appropriate formulation of the composition. If desired, such pressed bodies can also be drageed or film coated. Furthermore, the granulates can also be worked up 5 to give multi-layer tablets in that, for example, they are worked up to give a two-layer tablet with a second layer which contains a non-retarded initial dose. The granulates can also be filled into hard gelatine capsules, if desired after further coating the 10 granulate particles. Finally, it is also possible to work up several different retard granulates together to give, for example, a tablet.

The following comparative experiments show that the pharmaceutical compositions in accordance with, 15 and produced by the process according to, the present invention do not differ practically from conventional pharmaceutical compositions with regard to their disintegration time. For this purpose, the following active material-free powder mixture was prepared:

20	lactose	7500 g.
	finely powdered hydrogenated	
	castor oil (high melting	
	component - m.p. about 85°C)	500 g.
25	finely powdered stearic acid	
	(low melting component -	
	m.p. about 55°C).	2000 g.
	pulverised carboxymethyl -	
	cellulose	100 g.

30 The powder mixture was worked up in various ways to give tablets, the disintegration times of which were then determined in simulated digestive juice according to the procedure given in National Formulary, XIV Edition, I. Conventional production (melt at 100°C) page 978:

35 The powder mixture was heated in a low speed mixing kneader at 100°C, kneaded for 15 minutes and the mass, after cooling to ambient temperature, ground to give a granulate. Tablets with a definite

specification were pressed therefrom (tablet diameter 11 mm., thickness 5.2 mm., breaking strength 90 N).

II. Process according to the present invention (melt at 60°C) - alternatives A to E.

5      A) The powder mixture was heated to 60°C according to the process of the present invention in a high speed rapid mixer, compressed for 5 minutes and, after cooling to ambient temperature, ground to give a granulate. Tablets were pressed therefrom with the specification given in I above.

10     B) The powder mixture was introduced into a cogwheel granulating machine, the rollers of which had been heated to about 40°C with warm water. The mass was extruded through the bores under the roller pressure at a temperature of 54°C. The sieve granulate thus obtained was ground to give a granulate from which tablets were pressed with the specification given in I above.

15     C) The powder mixture was heated to 60°C in a low speed planet mixing kneader, kneaded for 15 minutes and the mass, after cooling to ambient temperature, ground to give a granulate from which tablets were pressed with the specification given in I above.

20     D) The powder mixture was heated in a fluidised bed granulator, with occasional shaking, with an air supply at 85°C, the product temperature being 60°C. After cooling, the mass was ground and pressed to give tablets with the specification given in I above.

25     E) The powder mixture was moved about in a friction mixer at about 1300 r.p.m. until it had melted. Melting of the low melting component took place at about 60°C, after about 4 minutes. The mass was removed from the mixer and, after cooling to ambient temperature, ground to give a granulate from which tablets were pressed with the specification given in I above.

30

35

-10-

III. Pressing process without melting.

A) The powder mixture was heated in a high speed rapid mixture to 50°C, i.e. below the melting point of the lower melting component, consolidated for

5 minutes and, after cooling to ambient temperature, ground to give a granulate from which tablets were pressed with the specification given in I above.

B) The powder mixture was pressed, without heating, with conventional pressure to give tablets

10 with the specification given in I above. The breaking strength of the tablets was 72 N.

C) The powder mixture was pressed, without heating, under the highest possible pressing force as in B) to give tablets with a breaking strength of 88N.

15 However, because of the high pressing force used, the thickness of the tablets was 4.8 mm.

The following Table shows what percentage of the compositions had disintegrated after a given disintegration time:

20

T A B L E

	disintegration time	1 h.	2 h.	3.5 h.	5 h.	7 h.
25	I	22	30	45	80	95
	II A	22	33	48	74	94
30	II B	23	39	60	91	97
	II C	21	29	43	72	96
35	II D	31	48	65	83	97
	II E	21	32	44	69	93
	III A	42	62	75	90	96
	III B	82	84	85	88	99
	III C	83	85	86	88	99

It can be seen from the above Table that the compositions described under I generally correspond in their disintegration time with the products described under II.

-11-

In contrast, the products described under III show that, by means of simple pressing, even under the highest possible pressure, a useful retarding cannot be achieved; after at most 2 hours, the compositions of type III have, to a major extent, disintegrated.

5 The following Examples are given for the purpose of illustrating the present invention:-

Example 1.

10 Film-coated tablets containing 45 mg. norfenefrine hydrochloride.

Composition:

	lactose PhEur	2700 g
	norfenefrine hydrochloride	1000 g
	carboxymethylcellulose	50 g
15	hydrogenated castor oil	250 g
	stearic acid	1000 g

For the production of the retard tablets, all the above-mentioned materials were placed in a rapid mixer with a double wall and homogeneously mixed.

20 The double wall was heated until the mixture had reached a temperature of 60°C. The mass thereby coalesced and was removed and cooled to ambient temperature. The cooled mass was ground to give a granulate from which tablets were pressed with a 25 diameter of 9 mm and a weight of 225 mg, which tablets were then provided with a film coating.

Example 2.

Tablets containing 15 mg norfenefrine hydrochloride.

Composition:

30	lactose PhEur.	2700 g
	norfenefrine hydrochloride	1000 g
	carboxymethylcellulose	50 g
	hydrogenated castor oil	1583 g
	stearic acid	1000 g

35 A granulate was produced from the components in the manner described in Example 1, from which there were pressed tablets with a weight of 95 mg and a diameter of 6 mm.

-12-

Example 3

Tablets containing . . . 80 mg pentaerythrityl tetrinitrate.

## Composition:

5	pentaerythrityl tetrinitrate (about 16%)	3200 g
	lactose	500 g
	carboxymethylcellulose	50 g
	hydrogenated castor oil	250 g
	stearic acid	1000 g

10

For the production of retard tablets, the powdered raw materials were introduced into a planet mixer with a double wall and homogeneously mixed and heated until the powder mixture had reached a temperature of 60°C and had thereby coalesced. The mass was removed from the mixer while still warm and, after cooling, ground to give a granulate from which are produced tablets with a weight of 750 mg and a diameter of 11 mm.

20

Example 4.

Tablets containing 45 mg norfenefrine hydrochloride

## Composition:

	lactose, Ph. Eur.	2430 g
	norfenefrine HCl	900 g
25	carboxymethylcellulose	45 g
	magnesium stearate	450 g
	stearic acid	675 g

For the manufacture of sustained-release tablets all the substances were mixed homogeneously in a planetary mixer with a double lining. The double lining was heated until the mixture reached a temperature of 60°C.

After setting the mass was removed, cooled and ground into a granular form. The granules were pressed into tablets with a diameter of 9 mm and a weight of 225 mg.

-13-

Example 5.Tablets containing 40 mg isosorbide dinitrate

## Composition:

	isosorbide dinitrate,	
5	ground in lactose (25%)	240 g
	lactose, Ph. Eur.	145 g
	carboxymethylcellulose	5 g
	hydrated castor oil	25 g
	stearic acid	100 g
10	The powders were mixed homogeneously and the mixture heated to 60°C in a boiler with a double lining. The warm mass was forced through a wide-mesh sieve.	
	After cooling the mass was ground into tablet granules and pressed into oval-shaped tablets weighing	
15	343.3 mg.	

Example 6.Tablets containing 30 mg vincamin

## Composition:

	vincamin HCl	73.33 g
20	lactose, Ph. Eur.	296.67 g
	carboxymethylcellulose	5 g
	hydrated castor oil	25 g
	stearic acid	100 g
25	All the raw materials were thoroughly mixed and heated to 60°C in a water bath. The warm mass was passed through a granulating machine. After cooling the mass was ground into tablet granules, which were then pressed into tablets with a diameter of 9 mm and a weight of 225 mg. Each tablet contains about .33 mg	
30	of vincamin hydrochloride, which corresponded to 30 mg vincamin.	

CLAIMS: (for all states other than Austria)

1. A process for the production of a pharmaceutical composition with a retarded liberation of an active material, wherein an active material in finely divided form is mixed with both a finely divided high melting lipid or lipoid component and a finely divided low melting lipid or lipoid component, the resulting mixture of active material and lipid or lipoid components is brought to a temperature which is above the melting point of the low melting component but below the melting point of the high melting component, and the resulting mixture, after melting of the low melting component, is allowed to cool to below the melting point thereof and subsequently worked up to give a finished pharmaceutical composition, the terms "low melting" and "high melting" being used relatively with respect to each other.
2. A pharmaceutical composition with a retarded liberation of an active material, the pharmaceutical composition comprising the active material in finely divided form, a finely divided high melting lipid or lipoid component, and, acting as a means for holding together the active material and the high melting lipid or lipoid component, a low melting lipid or lipoid component which has been caused to melt and subsequently to re-solidify, the terms "low melting" and "high melting" being used relatively with respect to each other.
3. An invention according to claim 1 or 2, wherein the melting point of the low melting component is below 70°C.
4. An invention according to claim 3 wherein the melting point of the low melting component is in the range from 50 to 60°C.
5. An invention according to any preceding claim, wherein the melting point of the high melting component is above 70°C.
6. An invention according to claim 5, wherein the melting point of the high melting component is in the range from 80 to 100°C.

~15~

7. An invention according to any preceding claim, wherein the two lipid or lipoid components are used in a weight ratio in the range from 1:9 to 9:1.
8. An invention according to claim 7, wherein the weight ratio of the two lipid or lipoid components is in the range from 1:5 to 5:1.
9. An invention according to claim 8, wherein the weight ratio of the two lipid or lipoid components is in the range from 1:3 to 3:1.
10. A process according to any preceding claim, wherein the or each lipid or lipoid component is a fatty alcohol, a fatty acid, a lipophilic salt of a fatty acid, a glyceride or a wax-like material of vegetable, animal, mineral or synthetic origin.

CLAIMS (for Austria alone):

1. A process for the production of a pharmaceutical composition with a retarded liberation of an active material, wherein an active material in finely divided form is mixed with both a finely divided high melting lipid or lipoid component and a finely divided low melting lipid or lipoid component, the resulting mixture of active material and lipid or lipoid components is brought to a temperature which is above the melting point of the low melting component but below the melting point of the high melting component, and the resulting mixture, after melting of the low melting component, is allowed to cool to below the melting point thereof and subsequently worked up to give a finished pharmaceutical composition, the terms "low melting" and "high melting" being used relatively with respect to each other.
2. An invention according to claim 1, wherein the melting point of the low melting component is below 70°C.
3. An invention according to claim 2, wherein the melting point of the low melting component is in the range from 50 to 60°C.
4. An invention according to any preceding claim, wherein the melting point of the high melting component is above 70°C.
5. An invention according to claim 4, wherein the melting point of the high melting component is in the range from 80 to 100°C.
6. An invention according to any preceding claim, wherein the two lipid or lipoid components are used in a weight ratio in the range from 1:9 to 9:1.
7. An invention according to claim 6, wherein the weight ratio of the two lipid or lipoid components is in the range from 1:5 to 5:1.
8. An invention according to claim 7, wherein the weight ratio of the two lipid or lipoid components is in the range from 1:3 to 3:1.

-17-

9. A process according to any preceding claim, wherein the or each lipid or lipoid component is a fatty alcohol, a fatty acid, a lipophilic salt of a fatty acid, a glyceride or a wax-like material of vegetable, animal, mineral or synthetic origin.



European Patent  
Office

EUROPEAN SEARCH REPORT

0043254

Application number

EP 81 30 2895

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. CL.)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	<p><u>US - A - 4 132 753</u> (M.S. BLICHARE)</p> <p>* Column 1, line 44 - column 2, line 25; column 3, lines 27-41; examples 10, 4-9,13; claims 1-12 *</p> <p>--</p>	1-9	A 61 K 9/26
X	<p><u>FR - A - 2 011 960</u> (K.G. ERIKSSON et al.)</p> <p>* Page 2, lines 5-34; page 4, line 18 - page 5, line 13, line 22 - page 6, line 2, lines 15-21; examples 1-2; claims 1-5 *</p> <p>&amp; DE - A - 1 948 019</p> <p>&amp; US - A - 3 670 065</p> <p>--</p>	1-9	<p>TECHNICAL FIELDS SEARCHED (Int. CL.)</p> <p>A 61 K 9/26 9/22</p>
X	<p><u>FR - A - 2 273 512</u> (CHEMISCH-PHARMAZ. FABRIK ADOLF KLINGE)</p> <p>* Example 3; claims 1-3 *</p> <p>--</p> <p><u>US - A - 3 184 386</u> (DOUGLAS STEPHENSON)</p> <p>* Column 2, lines 29-51; examples 3-5 *</p> <p>--</p> <p><u>DE - A - 2 033 911</u> (BEECHAM GROUP)</p> <p>* Claims 1-5; page 2, line 26 - page 4, line 2 *</p> <p>&amp; US - A - 3 639 560</p> <p>-----</p>	1-9	<p>CATEGORY OF CITED DOCUMENTS</p> <p>X: particularly relevant A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention E: conflicting application D: document cited in the application L: citation for other reasons</p> <p>&amp; member of the same patent family. corresponding document</p>
<input checked="" type="checkbox"/> <p>The present search report has been drawn up for all claims</p>			
Place of search	Date of completion of the search	Examiner	
The Hague	01-10-1981	GERMINARIO	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**